Daily Archives: February 8, 2019

Infliximab (IFX) is effective for treatment of Ulcerative Colitis (UC) and Crohn’s Disease (CD). Therapeutic drug monitoring (TDM) performed during IFX maintenance treatment with a target trough level of 3-7 ug/mL has been shown to improve clinical o… Continue reading →

Although clinical efficacy of combination therapy with infliximab (IFX) and thiopurine has been demonstrated in Crohn’s disease (CD), it remains uncertain when to add thiopurine in CD patients treated with IFX. The present study aimed to clarify appr… Continue reading →

Infliximab (IFX) treatment intensification, consisting of dose escalation or interval shortening, is effective for restoring clinical response in patients with Crohn’s disease (CD). However, clinical data on the timing of IFX treatment intensificatio… Continue reading →

Methotrexate (MTX) is a well-known immunomodulator in the treatment of inflammatory bowel disease (IBD) and often combined with biological agents. The ideal MTX dose for combination therapy has not been determined. Our aim is to investigate the effect … Continue reading →

Thiopurine therapy is used as a standard of care in inflammatory bowel disease (IBD), but it might cause fatal myelosuppressive adverse events that require hospitalization. To reduce the risk of myelosuppression hospitalizations, a systematic clinical … Continue reading →

DEVELOP is a multicenter, international, prospective, observational registry of the long-term safety and clinical status of 6070 pediatric patients (pts) with inflammatory bowel disease (IBD) diagnosed prior to 18 years of age who were treated with ant… Continue reading →

Kaposi Sarcoma is an angioproliferative neoplasm found to be associated with human herpesvirus-8 (HHV8). Although this virus plays a role in the pathogenesis of the disease, in individuals who are human immunodeficiency virus (HIV) negative, it is exce… Continue reading →

DEVELOP is a multicenter, prospective, observational registry of the long-term safety and clinical status of 6070 pediatric patients with inflammatory bowel disease (IBD; Crohn’s disease [CD], ulcerative colitis [UC], or indeterminate colitis [IC]) t… Continue reading →

Lifelong immunosuppression is a cornerstone of management of immune-mediated inflammatory diseases (IMD). Older patients represent an increasingly large number of patients with these diseases but are particularly vulnerable to safety risks with therapy… Continue reading →

Proton pump inhibitors (PPI) are used to reduce the clinical manifestations of gastrointestinal reflux disease, but there is an increased risk of complications from Crohn’s disease and ulcerative colitis (IBD) associated with the use of PPI. PPI may … Continue reading →